Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
At a glance
- Drugs T-cell vaccine AlloVax (Primary) ; T-cell vaccine-AlloStim; T-cell vaccine-AlloStim
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Immunovative Therapies
- 18 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
- 10 Jul 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
- 10 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.